Clinical Trial

Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy

Study acronym: COMET
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single-center, randomized study aims to compare the intraoperative detection rates of axillary lymph nodes marked with carbon suspension versus metallic markers in breast cancer patients (T1-3N1M0) before neoadjuvant therapy. Primary endpoint: frequency of marked lymph node identification during surgery. Secondary endpoints: time from marking to surgery and quality of life (EORTC QLQ-BR23).
Trial Details
NCT Number NCT07106112
Lead Sponsor Saint Petersburg State University, Russia
Conditions Breast Cancer
Enrollment 110 participants
Start Date 2025-05-15
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-06